TGAT
B8FGn
Oct 21, Last price
2.44EUR
Name
Biofrontera AG
Chart & performance
P/E
—
P/S
4.17
EPS
—
Vol. 1Y
—
Shs. 5Y
-19.22%
Rev. 5Y
149.09%
Div Yld LY
—
Div Yld TTM
—
Revenues
37m
+22.93%
Net income
-18m
L+36.37%
CFO
-10m
L+260.48%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Leverkusen, Germany, Biofrontera AG is a biopharmaceutical firm established in 1997, dedicated to the innovation, development, and marketing of skincare therapies. Its primary offerings include Ameluz, paired with the BF-RhodoLED lamp, engineered to address mild to moderate actinic keratoses on the face and scalp, field cancerization, and aggressive squamous cell carcinoma. The company also provides RhodoLED XL for managing multiple dispersed lesions, Belixos, an advanced cosmetic line for sensitive and irritated skin, and Xepi, a solution targeting antibiotic-resistant bacterial infections. Biofrontera's products are distributed mainly across the United States, Europe, and Israel, and its operations are strengthened by a collaboration agreement with Maruho Co., Ltd.
Key people
Thomas Schaffer
Chief Financial Officer, Member of the Management Board · since 2013
Christoph Duenwald
Member of the Management Board, Chief Commercial Officer · since 2016
Ulrich Granzer
Chairman of the Supervisory Board · since 2016
Member of the Supervisory Board · since 2016
Reinhard Eyring
Member of the Supervisory Board · since 2018
Member of the Supervisory Board · since 2019
Headquarters & legal address
Hemmelrather Weg 201
Leverkusen, NW 51377
DE
Leverkusen, NW 51377
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||